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Abstract
Background: Negative symptoms are frequent in patients 
with schizophrenia and are associated with marked impair-
ments in social functioning. The efficacy of drug-based treat-
ments and psychological interventions on primary negative 
symptoms remains limited. The Positive Emotions Pro-
gramme for Schizophrenia (PEPS) is designed to improve 
pleasure and motivation in schizophrenia patients by target-
ing emotion regulation and cognitive skills relevant to apa-
thy and anhedonia. The main hypothesis of this study is that 
patients who attend 8 one-hour sessions of PEPS and treat-
ment as usual (TAU) will have lower total apathy-avolition 
and anhedonia-asociality composite scores on the Scale for 
the Assessment of Negative Symptoms (SANS) than patients 
who attend only TAU. Methods: Eighty participants diag-
nosed with schizophrenia or schizoaffective disorder were 
randomized to receive either TAU or PEPS + TAU. The par-
ticipants were assessed by independent evaluators before 
randomization (T0), in a post-test after 8 weeks of treatment 
(T1) and at a 6-month follow-up (T2). Results: The post-test 
results and 6-month follow-up assessments according to an 
intention-to-treat analysis showed that the apathy and an-
hedonia composite scores on the SANS indicated statistical-
ly greater clinical improvements in PEPS participants than in 
non-PEPS participants. In the post-test, anhedonia but not 
apathy was significantly improved, thus favouring the PEPS 
condition. These results were sustained at the 6-month fol-
low-up. Conclusions: PEPS is an effective intervention to re-
duce anhedonia in schizophrenia. PEPS is a short, easy-to-
use, group-based, freely available intervention that is easy to 
implement in a variety of environments (ClinicalTrials.gov ID: 
NCT02593058). © 2019 The Author(s) 
Published by S. Karger AG, Basel
Jérôme Favrod and Alexandra Nguyen made equal contributions as 
first authors; Philippe Golay and Charles Bonsack made equal contri-
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Background
Negative symptoms in schizophrenia are character-
ized by marked reductions in goal-directed behaviour, 
which can include speech, non-verbal behaviour and so-
cial behaviour [1]. This reduction in goal-directed be-
haviour hampers daily life functioning and interferes 
with the recovery process [2–5]. The distinction be-
tween primary negative symptoms, a core aspect of the 
illness, and secondary negative symptoms bears impor-
tant therapeutic implications [6]. Primary negative 
symptoms comprise the core features intrinsic to schizo-
phrenia. Secondary negative symptoms are transient 
and attributable to the effects of factors such as unre-
lieved positive symptoms, depression, extrapyramidal 
side effects of antipsychotic drugs or social isolation. 
Primary and secondary negative symptoms may be sim-
ilar in clinical expression, despite their contrasting aeti-
ologies [7]. Secondary negative symptoms often dimin-
ish with the resolution of their causative factors, but pri-
mary negative symptoms are likely to persist despite 
treatment with either conventional or second-genera-
tion antipsychotics. Indeed, the efficacy of drug-based 
treatments and psychological interventions against pri-
mary negative symptoms remains limited [8–10]. Thus, 
there is a clear clinical need to develop treatments for 
primary negative symptoms.
The recent literature has distinguished the negative 
symptoms associated with a diminished capacity to ex-
perience (apathy, anhedonia) from symptoms that are 
associated with a limited capacity for expression (emo-
tional blunting, alogia) [11–14]. The apathy-anhedonia 
syndrome tends to be associated with a poorer prognosis 
than symptoms related to diminished expression, sug-
gesting that the former is the severer facet of the psycho-
pathology of schizophrenia [13]. Few psychosocial in-
terventions have been developed with the specific inten-
tion of treating negative symptoms of schizophrenia. 
Cognitive behavioural therapy for negative symptoms is 
based on the premise that negative symptoms are main-
tained by dysfunctional beliefs that contribute to apa-
thy-anhedonia syndrome [15]. The cognitive techniques 
used in this approach aim to modify these dysfunction-
al beliefs. However, this intervention improves func-
tional outcomes but has no significant effect on anhedo-
nia. An alternative psychological intervention is to max-
imize positive emotions [16, 17]. The field of affective 
science [18, 19] has described emotion regulation strat-
egies that increase the frequency, intensity and duration 
of positive emotional experiences. These strategies in-
clude anticipating or remembering enjoyment, express-
ing emotions via non-verbal behaviours, directing con-
trolled attention towards positive experiences when they 
occur and sharing positive experiences with others. Sev-
eral studies indicate that individuals with negative 
symptoms of schizophrenia exhibit impaired positive 
emotion regulation strategies. For example, these indi-
viduals present a reduced capacity to anticipate pleasur-
able activities and envision the future [20, 21]. They re-
port lower levels of pleasure in savouring past, present 
and future events than normal controls [22]. They also 
manifest a reduced ability to express and maintain pos-
itive emotions [23, 24]. Finally, they tend to avoid inter-
personal interactions and anticipate a lower amount of 
pleasure in such interactions [25, 26].
The Positive Emotions Programme for Schizophre-
nia (PEPS) was developed in response to these issues 
[27]. PEPS is an intervention consisting of 8 one-hour 
sessions applied to groups of 5–10 participants. The aim 
of the programme is to increase cognitive control of pos-
itive emotions, including the anticipation and mainte-
nance of those emotions. The programme uses visual 
and audio materials as part of a PowerPoint presenta-
tion of slides projected onto a screen. A pilot study was 
conducted with participants who met the ICD-10 crite-
ria for schizophrenia or schizoaffective disorders [28]. 
Thirty-one participants completed the programme. 
Those who dropped out did not differ significantly from 
those who completed the programme. Participation in 
the programme was accompanied by statistically signif-
icant reductions in the total scores for avolition-apathy 
and anhedonia-asociality on the Scale for the Assess-
ment of Negative Symptoms (SANS), with moderate ef-
fect sizes. Furthermore, there was a statistically signifi-
cant reduction in depression on the Calgary Depression 
Scale for Schizophrenia (CDSS), with a large effect size. 
Emotional blunting and alogia remained stable during 
the intervention.
From this pilot study, the present randomized con-
trolled clinical trial was designed (ClinicalTrials.gov ID: 
NCT02593058) to compare PEPS and treatment as usu-
al (TAU). The goal of the study was to establish whether 
PEPS is clinically effective using a randomized, con-
trolled, assessor-blind trial. The main hypothesis was 
that 8 sessions of PEPS added to TAU would significant-
ly reduce the composite SANS scores for apathy/avoli-
tion and anhedonia/asociality compared with TAU 
only. This randomized clinical trial also tested whether 
the expected change was sustained at the 6-month fol-
low-up.
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Materials and Methods
Trial Design
This randomized controlled trial compares the PEPS combined 
with TAU (PEPS + TAU) to TAU alone. Participants diagnosed 
with a schizophrenia spectrum disorder underwent one of these 
interventions for 8 weeks. Tests were administered to evaluate in-
dividuals’ current psychopathology and ability to savour pleasure 
at the time of inclusion, at the end of the 8-week intervention and 
at the 6-month follow-up. Participants were evaluated at baseline 
(T0) and then randomized to either TAU or PEPS + TAU. Ran-
domization was completed in blocks of 6, 8, 10 or 12 participants 
depending on the number of available candidates to keep a short 
delay between the first evaluation and the start of the intervention. 
Once a block was recruited, an independent researcher (S.R.) re-
ceived participant numbers and performed randomization using 
http://www.randomization.com/. Participants were randomly as-
signed to two parallel groups in a 1: 1 ratio. They were then in-
formed of their allocation by the main investigator (J.F.) and the 
local investigators (A.I., A.B., G.T.) and asked to not disclose their 
allocation to the independent raters (C.F. and J.C.). Data were in-
dependently managed by a research assistant (J.P.). The interven-
tion consisted of 8 weekly 1-h sessions of PEPS. At the end of the 
intervention (i.e., 8 weeks later), participants were again assessed 
(T1) by raters who were maintained unaware of group allocation. 
A third assessment (T2) was performed 6 months later to measure 
the stability of changes.
Subjects
To be included in the study, participants were required to meet 
the ICD-10 criteria for diagnosis of schizophrenia or a schizoaffec-
tive disorder (F20, F25), to present a score of at least 2 on the over-
all SANS anhedonia scale, to be between 18 and 65 years of age, to 
be able to read and understand French and to demonstrate capac-
ity for consent according to the San Diego Brief Assessment of 
Capacity to Consent [29]. This tool measures a patient’s under-
standing of an information sheet. If the potential participant was 
unable to respond correctly to the questions asked after reading the 
sheet, the patient was excluded. The procedure can be conducted 
a maximum of two times. Exclusion criteria were evidence of an 
organic brain disease, a clinically significant concurrent medical 
illness or a learning disability that could interfere with participa-
tion in group sessions.
The participants were outpatients and were recruited in nurs-
ing homes and rehabilitation workshops in the cantons of Fribourg 
and Vaud (Fondation HorizonSud in Marsens, SISP SA in Laus-
anne, Fondation Stanislas in Montherod, Unit of Rehabilitation of 
the Community Psychiatry Service, Department of Psychiatry, 
Lausanne). Potential participants were invited to presentations 
that provided an overview of the trial. During these meetings, the 
principal investigator and the person responsible for the site ex-
plained the aims of the study and the extent and nature of partici-
pation in the study, including randomization, a description of the 
control and experimental interventions, and a description of the 
three evaluations (pre-, post- and follow-up evaluations). The pa-
tients were also informed about the confidentiality of the data and 
their right to withdraw from participation at any time without giv-
ing any explanation. The patients received a written description of 
the study. Once the participants expressed their interest, their un-
derstanding of the protocol of the study was verified with the Uni-
versity of California San Diego Brief Assessment of Capacity to 
Consent, an instrument that measures decisional capacity [29]. In 
cases of failure to understand the study goal, voluntary participa-
tion, right to withdraw, randomization or number of assessment 
points, patients were excluded. A research assistant assessed the 
participants for eligibility in the study and met the case manager 
of the participant. An experienced clinician verified the diagnosis. 
This study was approved by the Board of Human Research Ethics 
Committee of the Canton de Vaud (Board Name: Commission 
cantonale d’éthique de la recherche sur l’être humain, CER-VD; 
Approval No.: 446/15). This committee is affiliated with the Swiss 
Ethics Committees on research involving humans. All participants 
signed a written informed consent form.
Interventions
Treatment as Usual
TAU consists of psychiatric management by a clinical team 
composed of at least one psychiatrist, a social worker and/or a psy-
chiatric nurse, with additional access to community treatment or 
hospital admission. Treatment involves medication, regular office-
based or community contacts with the clinical team for treatment 
monitoring, and socialization groups, therapy and psycho-educa-
tional groups. No attempts were made to standardize this treat-
ment because TAU is tailored to each patient’s specific needs. Pa-
tients receiving only TAU were invited to participate freely in 
PEPS after the trial.
Positive Emotions Programme for Schizophrenia
PEPS is an intervention meant to reduce anhedonia and apa-
thy. The programme teaches skills to help overcome defeatist 
thinking and to increase the anticipation and maintenance of pos-
itive emotions. J.F. and A.N. conceived the programme. The inter-
vention development and the programme description have been 
published [27]. The French version of PEPS can be downloaded 
for free at www.seretablir.net/peps/. PEPS involves 8 one-hour 
group sessions, administered using visual and audio materials and 
presented as PowerPoint presentation slides projected onto a 
screen. The programme uses a collaborative, egalitarian approach. 
Group facilitators participate in sessions just as the participants do 
by doing the exercises, sharing their experiences and carrying out 
the given tasks. This style of animation allows group leaders to act 
as models and promote participant involvement [30]. The peda-
gogical concept underpinning PEPS was designed according to 
Kolb and Kolb’s model [31] of experiential learning. This model 
sees the learning process as the transformation of an experience 
into personal knowledge. The sequential organization of the learn-
ing activity starts with the learner going through an experience (the 
concrete experience phase). Next, the learner is invited to describe 
it and to give it a meaning (the reflective observation phase). Dis-
tancing oneself from the experience broadens the learner’s under-
standing, generalizing and developing concepts through more ab-
stract thought (the abstract conceptualization phase). The learner 
then initiates an experimental approach to validate the newly ac-
quired knowledge through reality tests (the active experimentation 
phase). The learning activities for each skill taught in PEPS always 
proceed via these four steps. The skills content includes changing 
defeatist performance beliefs, savouring pleasant experiences, ex-
pressing emotions by increasing behavioural expression, sharing 
pleasant experiences with others and anticipating pleasant mo-
ments in the future. To familiarize the participant with the training 
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materials, each session starts with a brief relaxation exercise using 
slowed breathing and mental focalization on savouring a pleasant 
experience. Group facilitators received a day’s training before lead-
ing a group themselves and were supervised for 2 one-hour periods 
during a cycle of 8 sessions. Group leaders were clinicians working 
in the different sites (social workers, nurses, peer practitioners). 
The groups were led by 2–3 group leaders. Supervision was pro-
vided by experienced clinicians and teachers (A.N. and L.F.).
Outcomes
Main Outcome
The main outcome is the reduction of the composite scores of 
apathy/avolition and anhedonia/asociality on the SANS (hereafter 
called the apathy and anhedonia SANS composite score). This out-
come aims to measure diminished experience syndrome. It is the 
weighted sum of the 3 items of the avolition and apathy subscale 
and the 4 items of the anhedonia and social withdrawal subscale of 
the SANS. The change is expected to remain at the 6-month fol-
low-up. The secondary outcomes are depression, anticipatory and 
consummatory pleasure, beliefs about savouring and social anhe-
donia. To control for secondary negative symptom delusions, hal-
lucinations, extrapyramidal side effects and depression are as-
sessed at T0.
Measures
The following data and scales were used at T0 (pre-test), T1 
(post-test) and T2 (6-month follow-up) as part of standardized 
interviews with an independent evaluator trained in their admin-
istration. The average time needed to complete the scales with the 
participants was 1 h.
The SANS [32] measures schizophrenia’s deficit symptoms 
within the framework of schizophrenic disorders. It comprises 25 
items, scored from 0 to 5. A definition of each item, including ex-
amples, facilitates a better understanding of the scale’s content. 
The rating system is ordinal, from 0 (absent) to 5 (severe). The 25 
items are grouped into five subscales of withdrawal or emotional 
poverty, alogia (lack of speech), avolition and apathy (lack of en-
ergy, lack of initiative), anhedonia and social withdrawal (loss of 
interests), and attention, and a score is assigned to each compo-
nent. The scale was translated into French with acceptable validity 
[33, 34].
The CDSS [35] includes 9 items: depression, hopelessness, self-
depreciation, guilty ideas of reference, pathological guilt, morning 
depression, early wakening, suicide and observed depression. This 
scale has been validated in French [36].
The Temporal Experience of Pleasure Scale (TEPS) contains 18 
items included in two subscales: anticipatory pleasure (10 items) 
and consummatory pleasure (8 items) [37, 38]. Responses to items 
fall on a 6-point Likert scale from 1 (very false for me) to 6 (very 
true for me). Both the total anticipatory and consummatory scores 
of the TEPS are used. This scale has also been validated in French 
[39].
The Anticipatory and Consummatory Interpersonal Pleasure 
Scale (ACIPS) [40] is designed to assess one’s ability to experience 
pleasure in the interpersonal domain. It is a 17-item self-report 
questionnaire measuring three constructs, including intimate so-
cial interactions, group social interactions and social bonding. The 
ACIPS is scored on a 6-point Likert scale, ranging from 1 (very 
false for me) to 6 (very true for me). The ACIPS focuses on inter-
personal pleasure. This scale is validated in French [41].
The Savoring Beliefs Inventory (SBI) is a self-assessment ques-
tionnaire composed of 24 items divided into three temporal orien-
tations, past, present and future, each represented by 8 items [42]. 
Half of the items are positively formulated, while the other half are 
negatively framed. Each item is rated on a 7-point Likert scale 
ranging from “strongly disagree” to “strongly agree.” The SBI has 
been translated to and validated in French. The French version of 
the SBI is a valid scale for measuring attitudes such as the ability to 
savour positive experiences, including anticipation, reminiscence 
or the present moment [43].
At the pre-test (T0), the following instruments are also used:
Collection of sociodemographic and clinical data filled in with 
the patient’s case manager and psychiatrist: age, sex, marital status, 
educational level, main source of income, living arrangements 
(e.g., nursing home, with family), psychiatric diagnosis, duration 
of illness, and actual treatment.
The Psychotic Symptom Rating Scales [44], French version 
[45], is a 17-item multidimensional measure of delusions and au-
ditory hallucinations. Symptoms are rated over the past 2 weeks. 
Two scales exist for auditory hallucinations (11 items) and delu-
sions (6 items). A 5-point ordinal scale is used to rate symptom 
scores (0–4).
The Simpson-Angus Scale [46], French version [47], is a 10-
item rating scale that has been used widely for the assessment of 
extrapyramidal side effects in both clinical practice and research 
settings [48]. Each item of the 10-item Simpson-Angus Scale is 
rated on a 5-point scale (0–4), and the mean score is obtained by 
adding the items and dividing by 10.
For all patients, the symptom-rating assessments were admin-
istered by clinicians trained to reliably administer these scales. 
Regular tests of interrater reliability were conducted. Intraclass 
correlations for the different scales were above 0.85. To assure the 
blinding of the raters, appointments were organized by the main 
investigator (J.F.) and the local investigators (A.I., A.B., G.T.). In-
dependent evaluators were present only at assessment times. They 
did not participate in clinical meetings or supervision and had dif-
ferent research meetings focusing on data collection. Participants 
were taught not to disclose their allocation to the evaluators before 
T1 and T2. A test for blinding was conducted after each assess-
ment. Raters were asked to guess the group allocation of the par-
ticipant and indicate the certainty of their guess on a form while 
describing any hints they received if they were certain of the par-
ticipant’s group allocation. At T1, 4 PEPS participants and 2 TAU 
participants gave an involuntary hint disclosing their allocation 
during the interview with evaluators, and a nurse disclosed the al-
location of 1 TAU participant by mistake. Three participants were 
wrongly allocated (2 TAU participants identified as PEPS partici-
pants and 1 PEPS participant as a TAU participant). Blinding was 
maintained at T2, and no newer disclosure of the allocation was 
highlighted.
Statistical Analysis
All analyses were conducted using the IBM SPSS Statistics 
package version 22. All statistical tests were two tailed, and sig-
nificance was set at the 0.05 level. From the pilot study [28], the 
sample size was calculated with an α set at 0.05, a β set conserva-
tively at 0.95 and an effect size f of 0.44 for the apathy and anhedo-
nia SANS composite score. Using an a priori computation for an 
ANCOVA, the proposed trial required a total sample size of 70 
participants for the two arms. With an estimated dropout rate of 
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16%, 84 participants were estimated to be needed, and approxi-
mately 110 potential participants were screened. Intention-to-
treat analysis was used for each outcome. The multiple imputation 
method was performed with 50 imputations using the fully condi-
tional specification method to impute missing data for the patients 
who completed the baseline but neither the post-test nor the 
6-month follow-up assessment. The multiple imputation process 
was stratified by treatment arm and involved regression of the rel-
evant outcome variables with missing information (dropouts with 
no end of treatment scores) on all the non-missing values of the 
baseline outcome measures (all variables in the first column of Ta-
ble 2) with the addition of age and gender. A multiple regression 
approach to ANCOVA was used to allow adequate pooling of the 
estimates. Differences between post-test and pre-test as well as dif-
ferences between 6-month follow-up and pre-test scores were 
treated as dependent variables, treatment condition was a fixed 
factor, and pretreatment scores were covariates. The improvement 
and deterioration of patients in the two groups were evaluated on 
the main outcome with the participants who were assessed at the 
post-test. Using the standard error of the difference and an α-level 
of 0.05, patients who scored 0.208 points lower or higher at the 
post-test were considered to have significantly improved or dete-
riorated.
Results
Figure 1 presents the Consolidated Standards of Re-
porting Trials (CONSORT) flow diagram indicating that 
111 participants were interviewed to determine their eli-
gibility for the randomized clinical trial. Thirty-one par-
ticipants were excluded: 12 did not meet the inclusion 
criteria, 9 declined participation, 7 failed the San Diego 
Brief Assessment of Capacity to Consent, and 3 were not 
fluent in French. Eighty participants were randomized 
into the two groups (i.e., TAU or PEPS + TAU; screening-
to-inclusion ratio: 72%), 40 in each group. Four partici-
pants later declined participation during the interven-
tion, 2 in the PEPS + TAU group, 1 in the TAU-only 
group, and 1 during the 6-month follow-up in the TAU-
only condition. Three participants were hospitalized, 1 in 
each group for psychiatric hospitalization and 1 in the 
TAU group for a chirurgical hospitalization. These 3 par-
ticipants were not available at post-test assessment points 
and were considered dropouts. This resulted in a dropout 
rate of 8.75% for the entire sample. The entire sample 
comprised 31 female and 49 male participants. Their 
Randomized (n = 80)
Allocated to TAU only (n = 40/40) 
– Received allocated intervention (n = 40)
Allocated to PEPS + TAU (n = 40/40)
– Received allocated intervention (n = 37)
–  Did not receive allocated intervention
 (2 discontinued participation and 1 
 was hospitalized during the intervention)  
Lost to post-test (hospitalization) (n = 2)
Discontinued participation (n = 1)
Lost to post-test (hospitalization, n = 1)
Discontinued participation (n = 2)
Analyzed at post-test and 6-month 
follow-up (n = 40)
Analyzed at post-test and 6-month 
follow-up (n = 40) 
Post-test
Analysis
Six-month 
follow-up
Enrolment Assessed for eligibility 
(n = 111) Excluded  (n = 31)
– Did not meet inclusion criteria (n = 12)
– Declined to participate (n = 9)
– Poor French (n = 3)
– Poor understanding of protocol (n = 7)
Allocation
Discontinued participation to the study in 
6-month follow-up (refusal) (n = 1)
Lost to 6-month follow-up (n = 0)
Fig. 1. CONSORT 2010 flow diagram.
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mean age was 39.90 years (SD 10.90), and their mean du-
ration of illness was 16.08 years (SD 9.67). Sixty-six par-
ticipants met the ICD-10 criteria for schizophrenia, and 
14 those for schizo-affective disorders. Their mean scores 
were 5.61 (SD 4.65) for depression on the CDSS, 0.27 (SD 
0.41) for extrapyramidal side effects on the Angus-Simp-
son Scale, 4.95 (SD 10.43) for hallucinations and 3.50 (SD 
5.68) for delusions on the Psychotic Symptom Rating 
Scales. These mean scores indicate that the sample had 
low values for depression, hallucination, delusion and ex-
trapyramidal symptoms (Table 1). In PEPS + TAU, 25 
participants attended 8 sessions of PEPS; 6 participants 7 
sessions; 1 participant 6 sessions; 1 participant 5 sessions; 
2 participants 4 sessions; 1 participant 3 sessions; and 1 
participant 2 sessions. On average, PEPS + TAU partici-
pants attended 90% of the programme.
All participants were recruited between January 2016 
and February 2017. The first group started in February 
2016, and the last one ended in May 2017; the last post-
test follow-up was in November 2017. No adverse events 
were reported during the entire trial.
Main Outcome
Apathy and anhedonia SANS composite scores de-
creased more in the PEPS + TAU group than in the TAU-
only group between pre-test (T0) and post-test (T1) as-
sessments with a medium effect size (B = –0.598, p = 
0.014, d = –0.55) (Table 2). This difference remained at 
the 6-month follow-up (T2) with a medium to large effect 
size in favour of the PEPS + TAU condition (B = –1.156, 
p = 0.001, d = –0.76) (Table 3). When looking at individ-
ual elements of the composite score, the SANS anhedo-
nia/asociality score improved with a medium effect size 
in favour of the PEPS + TAU condition (B = –1.557, p = 
0.012, d = –0.57) but not the SANS apathy/avolition score 
(B = – 0.685, p = 0.19, d = –0.30) (Table 2). At the 6-month 
follow-up, the anhedonia/asociality score improved with 
a medium to large effect size (B = – 3.102, p = 0.001, d = 
–0.78), and the apathy/avolition score improved with a 
small to medium effect size (B = 1.188, p = 0.045, d = 
–0.45) (Table 3).
Adding the Psychotic Symptom Rating Scales, CDSS 
and Simpson-Angus Scale at the pre-test as covariates did 
Table 1. Baseline characteristics of the TAU and PEPS + TAU groups
TAU
(n = 40)
PEPS + TAU
(n = 40)
Sociodemographic characteristics
Sex female/male 12/28 19/21
Age (SD), years 39.83 (10.27) 39.98 (11.62)
Marital status: currently married 4 2
Educational level: secondary 8 8
Main source of income: state aid 38 40
Living situation: independent living 17 15
Clinical variables
ICD-10 diagnosis
Schizophrenia 34 32
Schizoaffective disorders 6 8
Duration of illness (SD), years 15.55 (10.18) 16.60 (9.23)
Actual treatment
Chlorpromazine equivalent (SD) 281 (198) 383 (352)
Fluoxetine equivalent (SD) 23.65 (34.56) 36.75 (78.85)
Main outcome variable
Composite score: apathy and anhedonia (SD) 4.08 (1.89) 3.76 (2.10)
Calgary Depression Scale for Schizophrenia (SD) 5.78 (5.19) 5.45 (4.10)
Simpson-Angus Scale (SD) 0.30 (0.48) 0.23 (0.34)
PSYRATS Hallucination (SD) 4.03 (9.92) 5.88 (10.96)
PSYRATS Delusions (SD) 3.90 (6.05) 3.10 (5.33)
TAU, treatment as usual; PEPS, Positive Emotions Programme for Schizophrenia; SD, standard deviation; 
PSYRATS, Psychotic Symptom Rating Scales.
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not change the pattern of the results. To evaluate the ro-
bustness of our findings, a complete case analysis was also 
performed on the main outcomes. The same pattern of 
findings could be obtained with either the original data or 
the pooled results of the 50 imputed data sets. A second 
analysis was also performed excluding those people 
whose allocation had been accidentally revealed. The 
same pattern of findings was obtained with the exception 
of the SANS apathy/avolition score at the 6-month fol-
low-up, which was no longer significant (p = 0.146 in-
stead of p = 0.045). Table 4 compares the changes in the 
main outcome of the participants. Forty-nine percent of 
patients in the TAU group had significantly improved 
scores, 11% had unchanged scores, and 41% had deterio-
rated scores. In the TAU + PEPS group, 68% of partici-
pants improved, 19% remained unchanged, and 14% 
worsened. A series of logistic regressions was performed 
to verify whether deterioration could be predicted by any 
of the sociodemographic or baseline data. Only age was 
significantly associated with a higher likelihood of dete-
rioration during the TAU + PEPS intervention (odds ra-
tio = 1.115, p = 0.039). While the mean age was 39.98 years 
in this group, the patients who deteriorated were 63, 60, 
55, 40 and 37 years old. 
Secondary Outcomes
Concerning the secondary outcomes, the TEPS antici-
patory and consummatory scores were significantly im-
proved with a medium effect size at the post-test (T1) 
(Table 2). At the 6-month follow-up (T2), the TEPS con-
summatory score showed sustained improvement with a 
medium effect size. The ACIPS group social interactions 
score and the SBI total score were significantly improved 
with a medium effect size at the 6-month follow-up. The 
SBI was improved mainly on the present-moment plea-
sure scale (Table 3).
The other subscales of the SANS were not significant-
ly improved at the post-test for affective flattening, alogia 
and attention, or at 6 months for alogia and attention. 
Only affective flattening is improved at the 6-month fol-
Table 2. Between-group differences at the post-test (T1) and pre-test (T0) on ANCOVA (means and SD in parentheses)
TAU (n = 40) TAU + PEPS (n = 40) Differences (T1–T0)a B
group
effect
p d
T0 T1 T0 T1 TAU PEPS + TAU
Main outcome
SANS composite score
apathy and anhedonia 4.08 (1.89) 3.81 (1.84) 3.76 (2.10) 2.96 (2.01) –0.23 (1.07) –0.83 (1.09) –0.598 0.014 –0.55
SANS apathy score 5.05 (3.47) 4.77 (3.32) 4.65 (3.19) 3.80 (3.32) –0.23 (2.26) –0.91 (2.38) –0.685 0.192 –0.30
SANS anhedonia score 9.58 (3.86) 8.89 (4.11) 8.85 (5.01) 6.78 (4.57) –0.60 (2.79) –2.16 (2.71) –1.557 0.012 –0.57
Secondary outcomes
SANS affective flattening
score 7.63 (6.35) 7.06 (7.32) 8.88 (7.82) 6.22 (6.84) –0.75 (5.14) –2.47 (4.95) –1.720 0.123 –0.34
SANS alogia score 3.15 (3.24) 3.34 (3.21) 3.93 (3.83) 3.57 (3.54) 0.03 (2.69) –0.18 (2.80) –0.208 0.737 –0.08
SANS attention score 2.98 (2.29) 2.89 (2.91) 3.40 (2.90) 3.01 (2.46) –0.17 (2.37) –0.31 (2.11) –0.132 0.791 –0.06
SANS sum of subscores 28.38 (15.04) 26.95 (15.30) 29.70 (18.20) 23.38 (15.76) –1.57 (8.51) –6.18 (8.38) –4.612 0.015 –0.55
CDSS 5.78 (5.19) 4.31 (3.65) 5.45 (4.10) 3.46 (3.23) –1.37 (2.97) –2.09 (2.87) –0.725 0.261 –0.25
TEPS anticipatory 39.48 (11.61) 39.82 (10.61) 43.68 (9.51) 46.17 (9.11) 0.40 (7.32) 3.24 (7.06) 3.635 0.025 0.51
TEPS consummatory 32.13 (7.77) 32.41 (6.75) 36.58 (7.00) 38.24 (6.67) –0.80 (5.92) 2.75 (5.70) 3.552 0.007 0.61
ACIPS intimate social 
interactions 34.33 (8.05) 34.66 (8.31) 35.30 (7.80) 35.58 (7.91) 0.13 (6.70) 0.48 (6.63) 0.345 0.818 0.05
ACIPS group social 
interactions 17.63 (4.84) 17.56 (5.94) 18.38 (5.47) 19.16 (4.80) –0.16 (4.12) 0.87 (4.07) 1.031 0.263 0.25
ACIPS social bonding 22.50 (5.68) 21.78 (6.06) 22.15 (4.82) 23.03 (5.45) –0.67 (4.42) 0.83 (4.36) 1.498 0.128 0.34
SBI total 16.33 (28.70) 21.10 (26.42) 18.73 (21.36) 29.20 (26.05) 4.33 (21.09) 10.92 (20.88) 6.594 0.157 0.31
SBI anticipating pleasure 6.03 (10.83) 7.36 (9.95) 7.30 (9.05) 10.49 (11.30) 1.07(9.07) 3.46 (8.92) 2.385 0.228 0.27
SBI present-moment 
pleasure 3.90 (11.46) 5.46 (11.33) 4.43 (8.00) 8.78 (9.04) 1.44 (8.77) 4.47 (8.74) 3.029 0.123 0.35
SBI reminiscing pleasure 6.40 (10.37) 8.27 (9.95) 7.00 (8.54) 9.94 (9.15) 1.74 (8.03) 3.07 (7.87) 1.326 0.457 0.17
TAU, treatment as usual; PEPS, Positive Emotions Programme for Schizophrenia; SD, standard deviation; SANS, Scale for Assessment of Negative 
Symptoms; CDSS, Calgary Depression Scale for Schizophrenia; TEPS, Temporal Experience of Pleasure Scale; ACIPS, Anticipatory and Consummatory 
Interpersonal Pleasure Scale; SBI, Savouring Beliefs Inventory – French version. a Estimated means obtained from ANCOVA after controlling for baseline.
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low-up. The sum of the five subscales of the SANS was 
statistically decreased with a medium effect size at the 
post-test (Table 2) and a large effect size at the 6-month 
follow-up (Table 3) favouring the experimental condi-
tion.
Discussion
The aim of this randomized controlled trial was to in-
vestigate the effect of a short group intervention (PEPS) 
on apathy and avolition in schizophrenia. PEPS led to 
moderate to large improvement in the primary outcome 
of apathy and anhedonia SANS composite score and 
moderate improvement in secondary outcomes of antici-
patory and consummatory pleasure, as well as social in-
teractions compared with the control group. Effects were 
maintained at the 6-month follow-up for the main out-
come. There were no differences between groups on mea-
sures of alogia and attention. Participation in the entire 
program was high, while attrition was low, and no adverse 
events were reported. The results indicate that 8 sessions 
of PEPS intervention effectively reduced the diminished 
capacity to experience syndrome in a clinical sample suf-
fering from schizophrenia.
In the present study, between-group effects on apathy/
avolition and anhedonia/asociality at the post-test (d = 
–0.55) and 6-month follow-up (d = –0.76) were similar to 
the effects on apathy/avolition (d = –0.66) of an 18-month 
recovery-oriented cognitive therapy programme to im-
prove psychosocial functioning and negative symptoms 
Table 4. Participants who exhibited improved, unchanged or 
worsened main outcomes on the post-test
TAU + PEPS, % 
(n = 37)
TAU, % 
(n = 37)
Improved 68 (n = 25) 49 (n = 18)
Unchanged 19 (n = 7) 11 (n = 4)
Worsened 14 (n = 5) 41 (n = 15)
Table 3. Between-group differences at the 6-month follow-up (T2) and pre-test (T0) on ANCOVA
TAU (n = 40) TAU + PEPS (n = 40) Differences (T2–T0)a B
group
effect
p d
T0
mean (SD)
T2
mean (SD)
T0
mean (SD)
T2
mean (SD)
TAU
mean (SD)
PEPS + TAU
mean (SD)
Main outcome
SANS composite score apathy 
and anhedonia 4.08 (1.89) 3.73 (1.94) 3.76 (2.10) 2.40 (1.86) –0.28 (1.54) –1.43 (1.52) –1.156 0.001 –0.76
SANS apathy score 5.05 (3.47) 4.35 (3.38) 4.65 (3.19) 2.96 (2.85) –0.61 (2.64) –1.79 (2.63) –1.188 0.045 –0.45
SANS anhedonia score 9.58 (3.86) 9.14 (4.44) 8.85 (5.01) 5.65 (4.81) –0.26 (4.00) –3.37 (3.98) –3.102 0.001 –0.78
Secondary outcomes
SANS affective flattening  
score 7.63 (6.35) 7.28 (6.97) 8.88 (7.82) 5.68 (5.36) –0.63 (4.95) –2.91 (4.83) –2.280 0.038 –0.47
SANS alogia score 3.15 (3.24) 2.88 (2.93) 3.93 (3.83) 2.29 (2.64) –0.49 (2.37) –1.42 (2.30) –0.929 0.075 –0.40
SANS attention score 2.98 (2.29) 2.18 (2.42) 3.40 (2.90) 2.15 (2.55) –0.91 (2.26) –1.13 (2.18) –0.220 0.659 –0.10
SANS sum of subscores 28.38 (15.04) 25.84 (15.54) 29.70 (18.20) 18.74 (12.95) –2.80 (10.22) –10.70 (10.07) –7.903 <0.001 –0.78
CDSS 5.78 (5.19) 3.66 (5.04) 5.45 (4.10) 2.01 (2.46) –2.02 (3.69) –3.54 (3.39) –1.525 0.054 –0.43
TEPS anticipatory 39.48 (11.61) 40.27 (11.58) 43.68 (9.51) 45.51 (8.27) –0.08 (8.29) 2.72 (7.79) 2.801 0.118 0.35
TEPS consummatory 32.13 (7.77) 33.68 (6.65) 36.58 (7.00) 38.67 (5.78) 0.41 (5.41) 3.23 (4.93) 2.822 0.016 0.55
ACIPS intimate social
interactions 34.33 (8.05) 35.13 (7.66) 35.30 (7.80) 37.67 (8.79) 0.61 (6.63) 2.57 (7.03) 1.966 0.210 0.29
ACIPS group social
interactions 17.63 (4.84) 17.98 (4.74) 18.38 (5.47) 20.13 (4.07) 0.18 (3.77) 1.93 (3.63) 1.757 0.033 0.48
ACIPS social bonding 22.50 (5.68) 22.74 (5.54) 22.15 (4.82) 23.50 (6.37) 0.32 (5.21) 1.27 (5.43) 0.946 0.419 0.18
SBI total 16.33 (28.70) 20.16 (28.93) 18.73 (21.36) 31.55 (24.01) 3.51 (19.33) 13.15 (19.21) 9.643 0.026 0.50
SBI anticipating pleasure 6.03 (10.83) 6.81 (11.25) 7.30 (9.05) 10.95 (11.34) 0.60 (8.96) 3.85 (8.97) 3.252 0.110 0.36
SBI present-moment pleasure 3.90 (11.46) 5.26 (10.91) 4.43 (8.00) 10.74 (7.96) 1.24 (8.01) 6.44 (7.89) 5.196 0.003 0.65
SBI reminiscing pleasure 6.40 (10.37) 8.08 (12.29) 7.00 (8.54) 9.85 (9.06) 1.57 (9.37) 2.96 (8.66) 1.397 0.488 0.15
TAU, treatment as usual; PEPS, Positive Emotions Programme for Schizophrenia; SD, standard deviation; SANS, Scale for Assessment of Negative 
Symptoms; CDSS, Calgary Depression Scale for Schizophrenia; TEPS, Temporal Experience of Pleasure Scale; ACIPS, Anticipatory and Consummatory 
Interpersonal Pleasure Scale; SBI, Savouring Beliefs Inventory – French version. a Estimated means obtained from ANCOVA after controlling for baseline.
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in low-functioning patients with schizophrenia [15]. 
However, when splitting the composite score, PEPS ap-
pears to be mainly effective in reducing the SANS anhe-
donia/asociality score. The benefit on the SANS apathy/
avolition score obtained at the 6-month follow-up was 
lost when participants whose group allocation had been 
accidentally revealed were excluded. The significant re-
duction in the SANS anhedonia/asociality score in the 
PEPS + TAU group compared with the TAU-only arm is 
particularly promising because the intervention is spe-
cifically intended to maximize positive emotion experi-
ences. The results suggest that anhedonia involves psy-
chological processes such as emotion regulation skills 
that can be trained, indicating that anhedonia does not 
constitute a mere experiential abnormality. Patients could 
learn positive emotion regulation skills despite potential 
cognitive impairments in working memory and long-
term memory. The fact that the SANS apathy/avolition 
score did not significantly improve is not surprising be-
cause PEPS is a very short intervention and focuses on 
positive emotion regulation training. Since apathy and 
anhedonia are frequently considered overlapping symp-
toms resulting from the same underlying process [49], it 
was expected that improving pleasure would increase 
goal-oriented behaviours. However, the results suggest 
that improving pleasure is not enough to improve moti-
vation. Research evidence indicates that patients with 
schizophrenia have a reduced capacity for decision mak-
ing related to reward; particularly, patients with schizo-
phrenia exhibit slowed ability to modulate behaviour to 
seek rewards [50]. In the present study, an improvement 
in apathy would probably have required adjunctive train-
ing in instrumental and social skills.
At the post-test (T1), the anticipatory and consumma-
tory scales of the TEPS were significantly improved, but the 
other self-report scales were not changed. The improve-
ment was sustained at the 6-month follow-up for the con-
summatory scale, but not the anticipatory scale of the 
TEPS. The present-moment scale of the SBI showed an im-
provement at the 6-month follow-up. The ACIPS group 
social interaction score was also significantly improved, fa-
vouring PEPS + TAU. The results of these self-report scales 
are in line with the reduction in the anhedonia-asociality 
score of the SANS, showing that PEPS improves current 
pleasure for the TEPS and the SBI. Anticipatory and ac-
tual pleasure were distinguished in an attempt to explain 
the fact that patients engage in fewer reward-seeking be-
haviours despite a seemingly intact capacity to experience 
pleasure. Studies have indicated that individuals with 
schizophrenia predict that future events will result in less 
pleasure than their control counterparts [38, 39, 51]. In a 
replication study using the TEPS with another cohort of 
schizophrenia subjects, the opposite result was obtained. 
Schizophrenia subjects self-reported a difference in con-
summatory pleasure but not anticipatory pleasure com-
pared with controls [52]. In another study, there were no 
significant differences in either consummatory or antici-
patory pleasure between schizophrenia and healthy con-
trol groups, except for patients with high levels of amotiva-
tion who were impaired on both dimensions [53]. Frost 
and Strauss [54] advocated that scales with a hypothetical 
self-report format do not rely on experiential emotion but 
rather on semantic emotion knowledge and cannot mea-
sure consummatory pleasure or anticipatory pleasure. 
They suggested that a better measure would involve asking 
participants how they feel in the moment when directly 
exposed to a situation. The present study shows that a re-
duction in the anhedonia-asociality scale score of the SANS 
measured by independent raters is associated with im-
proved current pleasure self-ratings by patients. The spe-
cific improvement in the ACIPS group social interaction 
may be directly related to the group format of PEPS, in 
which patients could have experienced pleasure together.
Only 14% of participants who received PEPS deterio-
rated on the main outcome at the post-test compared 
with 41% in the TAU-only group. The deterioration in 
the PEPS arm was associated with the age of the partici-
pants. While this finding must be replicated, PEPS inter-
vention may not be as effective in older patients.
Important strengths of this study were the randomized 
design, high retention rate, controlled sources of second-
ary negative symptoms and high intervention acceptabil-
ity. The study retention rate was high, and 91.25% of par-
ticipants remained in the study until its end. The study 
was sufficiently powered to test the hypothesis according 
to the sample size calculation and the minimal dropout 
rate. The interrater reliability was good (intraclass coef-
ficient correlation > 0.85), and the blindness of the asses-
sors was maintained for 91% of the participants until the 
6-month follow-up by a clear separation between the clin-
ical and assessment teams. The study also controlled for 
sources of secondary negative symptoms such as depres-
sion, psychosis and extrapyramidal side effects. Partici-
pants who were randomized to the PEPS + TAU group 
attended 90% of the sessions. This high attendance rate is 
attributable to the fact that the participants described the 
programme as attractive. The participants appreciated 
the involvement of the group leaders in the exercises and 
valued the emphasis on positive aspects of their lives rath-
er than on symptoms and deficits.
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The main limitation of this study is the absence of an 
active control group. Certainly, group psychotherapeutic 
treatments can improve negative symptoms in the treat-
ment of schizophrenia compared with TAU and appear 
to be non-specific and positively related to group inten-
sity [55]. The collaborative, egalitarian approach used in 
the programme may have played an important role in the 
improvement of patients, making the patients more com-
mitted to treatment [56]. However, the selective effect on 
anhedonia suggests that this placebo effect is not suffi-
cient for other negative symptoms, except potentially for 
affective flattening at the six-month follow-up, suggest-
ing a specific effect of PEPS on anhedonia. Contrary to 
what is usually presumed, a meta-analysis showed that 
the negative symptoms of schizophrenia tend to improve 
significantly and consistently in outpatient settings, with 
a greater reduction found on the SANS than on the 
PANSS [57]. In the present study, the improvement in the 
SANS sum of subscores in the TAU arm (within-group 
Cohen’s d = 0.166) matches the small improvement ob-
served in the non-drug intervention of this meta-analysis, 
suggesting that TAU acts as a consistent control group. 
The SANS sum of subscores in the PEPS + TAU arm 
(within-group Cohen’s d = 0.940) is superior to those re-
ported in the non-drug studies reviewed in this meta-
analysis.
Although traditional interventions have focused pre-
dominantly on ways to reduce negative emotions, inter-
ventions to improve positive emotions have been very re-
cently developed to treat psychiatric disorders [58, 59]. A 
shift from approaches focusing on disease to well-being is 
increasingly advocated [60]. For example, well-being 
therapy [61] was developed in the 1990s as an adjunctive 
treatment to increase the level of recovery and has been 
found to be effective in depression and cyclothymic disor-
ders and to promote psychological well-being in educa-
tional settings. The use of well-being therapy to improve 
functional outcomes as an additional component to psy-
chological treatments in psychotic disorders was postu-
lated in 2004 [62]. Along this line of thought, the PEPS is 
a specific positive emotion regulation skills training inter-
vention for patients with schizophrenia. The applications 
issued from positive psychology interventions with pa-
tients suffering from schizophrenia are infrequent [63]. 
The main interventions that have been tested with pa-
tients suffering from schizophrenia or related psychosis 
are mindfulness [64], acceptance and commitment thera-
py [65], love kindness meditation [66] and compassion 
therapy [67]. These interventions are difficult to compare 
with the intervention in the current study; although they 
involve emotion regulation techniques, PEPS focuses on 
learning positive emotion regulation skills. To our knowl-
edge, the only intervention comparable to the PEPS is a 
positive intervention called WELLFOCUS PPT, which 
has been tested in a controlled study on patients with psy-
chosis [63]. The programme aims to increase positive ex-
periences, amplify strengths, foster positive relationships 
and create a more meaningful self-narrative. The results 
showed an improvement in the Brief Psychiatric Rating 
Scale and depression. However, the study did not distin-
guish positive from negative symptoms. Additionally, the 
effect sizes for these outcomes are small to moderate.
This paradigm should be repeated in other environ-
ments to confirm the results. It would also be useful to 
develop a tailored individual version of the therapy for 
patients with severer anhedonia complemented with oth-
er emotion regulation strategies to improve positive emo-
tions, such as those described in the model of Quoidbach 
et al. [68]. Clinical practice requires interventions that 
can be applied directly to the patient’s bed. PEPS is freely 
available on the Internet, but translation to other lan-
guages and development of an interactive e-learning plat-
form to train group leaders are necessary.
Further studies are needed to more precisely assess the 
impact of emotion regulation strategies on endocrine and 
autonomic stress in schizophrenia because maladaptive 
emotion regulation strategies may render people vulner-
able to mental health problems in general [69]. Impaired 
subjective well-being is also associated with reduced an-
terior cingulate activity during reward processing, which 
may lead to a reduction in the integration of environmen-
tal stimuli and reward outcomes [70]. Future research 
should scrutinize the impact of the intervention on bio-
logical variables.
In summary, the present study shows that a short, 
easy-to-use, group-based intervention such as PEPS may 
be efficacious in reducing anhedonia in patients with 
schizophrenia. Considering the relatively brief and group-
based nature of the intervention, PEPS could be a cost-
effective intervention to implement for patients with neg-
ative symptoms of schizophrenia as an adjunctive treat-
ment to social skills training [71] or other psychosocial 
interventions.
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